Connect with us

Featured

One Company That Could Have A Leg Up On Marijuana Market Leaders – It Comes Down To Having “Patients”

Joe Samuel

Published

on

marijuana pharmacy

We’re all aware of the biggest names in the cannabis industry right now. Companies like Canopy Growth, Aphria, Tilray, Cronos Group, and Aurora Cannabis are all mentioned when we see reports about “Market Leaders” in marijuana. The interesting part: there may be other businesses out there that could be built on a much more streamlined platform and could offer almost immediate access to the market potential ahead…


Building A Company Just Takes “Patients”


Canopy Growth reported 84,400 registered patients at September 30, 2016. In its latest financial report, Aurora Cannabis for example, reported that it had 67,484 active registered patients and this was up from roughly 43,000 during the prior quarter. Meanwhile you have funds like Vanguard Total Intl Stock Idx Fund, Golden Opportunities Diversified, Vanguard Developed Markets Index Fund, Vanguard FTSE All-Wld ex-US SmCp Idx Fd, iShares Core S&P/TSX Capped Compost ETF, and the two cannabis industry ETFs: Horizons Marijuana Life Sciences ETF & ETFMG Alternative Harvest ETF among others, holding more than a cumulative 40 million shares of Aurora in their portfolios (1).

But what if you found out that there’s another company out there that not only has over 100,000 patients (compared to Aurora’s less than 70,000) but also has built a diversified business model (like Aurora) targeting both the traditional healthcare market in addition to legal cannabis? Also, in comparison to Aurora’s $5.50+ per share price tag, the company I’m talking about is trading around 1/10th of that figure.

healthvue

The company being discussed: Premier Health Group Inc., (OTC: PHGRF) (CSE: PHGI). Premier is developing innovative healthcare approaches that combine human skill based expertise with emerging technologies. Where the cannabis industry could come into play is with the company subsidiary HealthVue and its list of patients over 100,000 strong…that’s right…more than one hundred thousand ACTIVE patients.

Premier Health Group Inc., (OTC: PHGRF) (CSE: PHGI) has engaged discussions with Licensed Producers under the Access to Cannabis for Medical Purposes Regulation (ACMPR), other licensed medical cannabis companies and government officials in order to establish a framework for both patient and physician education. The company’s CEO said it perfectly:

“With over 110,000 active patients in our clinic ecosystem it is important that we provide them with the best possible information that allows them to make informed decisions about their personal and family’s health. Providing our family physicians with the appropriate tools and knowledge to prescribe cannabis or with the ability to refer patients to a specialist within our clinics is a key outcome of this initiative.”

-Dr. Essam Hamza , CEO of Premier Health Group Inc., (OTC: PHGRF) (CSE: PHGI)


Canadian Market Could Offer Opportunity For Premier Health Group Inc., (OTC: PHGRF) (CSE: PHGI).


1. The Canadian retail pharmacy market is estimated to be $44 billion (Source: IBISWorld). It is expected the industry sector will continue to allow for favorable economics for pharmacy operators as baby boomer’s demand increases for prescriptions and operators to expand the scope of practice to include preventative services.

2. The Canadian medical cannabis clinic market is estimated to be worth approximately $2.35 billion by 2025.

If these two facts weren’t enough, there is also a MAJOR Cross Over in Canada that connects medical cannabis & retail pharmacies. For some reason, news outlets aren’t paying attention to it right now either.

The crossover: Canadian pharmacies are fully behind medical marijuana too! Shoppers, Lovell Drugs and PharmaChoice have all signed supply deals with leading cannabis producers in Canada. Their pending entry into the medical cannabis market comes as the number of registered MMJ patients is soaring.

Premier Health Group Inc., (OTC: PHGRF) (CSE: PHGI) could have an ideal business model in progress that would vertically integrate cannabis as another growth opportunity. Also consider that industry peers like Aurora Cannabis don’t hold a flame to the number of active patients that Premier Health Group has and the numbers could really start to make a lot more sense once eyes begin to open on the street.

Again, just an opinion but when you compare the two, though Aurora is (finally) generating revenue, Premier Health is still in the early stages of growth yet already has access to a pool of patients that is more than 50% larger in size than Aurora and more than 15% to that of Canopy. It may all come down to timing of it all. As healthcare takes a center stage position during the latest bout of market volatility and cannabis legalization remains a focus of funds, looking for the next “star” to shine.

telehealth_healthcare_technology_stocks

(1) As of Tue 27/11/2018 According to Morningstar http://quote.morningstar.ca/Quicktakes/owners/MajorShareholders.aspx?t=ACB&region=CAN&culture=en-CA

DISCLAIMER:  Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 ( CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the “500,000” shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click here for full disclaimer.

Continue Reading
Click to comment

Biotechnology

Will Biotech Stocks Soar Into 2020?

Joe Samuel

Published

on

best biotech stocks to trade now

The stock market has been on a wild ride this year and December has shown no difference. When it comes down to it, making money in the stock market is simple. But it isn’t easy; let me explain.

For instance, if a sector is on the upward trajectory then it makes complete sense to have a look at some of the stocks in that arena. But then again, even if the sector is hot, it doesn’t mean every stock within it is.

Regardless, among the sectors that have shown impressive growth over the past few years biotech remains positive. and many investors have managed to make handsome returns. Here is a look at two biotech stocks that are worth considering at this point.

Tonix Pharmaceuticals Holding

The first biotech stock that could be out into the watch list is that of Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) after the company made an important announcement. Tonix announced that it has been granted a patent by the European Patent Office for “Eutectic Formulations of Cyclobenzaprine Hydrochloride and Mannitol”.

The patent gives Tonix access to as many as 14 claims and also gives the company exclusive rights up until 2034. The development is a significant one and could have far-reaching implications for Tonix’s business in the years to come.The news was well-received by the markets as well and the stock rallied by as much as 23% on Thursday.

VBI Vaccines

The other stock that could be taken under consideration is the VBI Vaccines Inc (NASDAQ:VBIV). The company made a major announcement with regards to the Phase 1/2A study of its cancer vaccine immunotherapeutic In recurrent glioblastoma (GBM) patients medicine VB1-1901.

The company announced that it presented the data regarding the medicine at the 24th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology. The event in question is an influential one and is a substantial achievement for VBI. The stock rallied by as much as 50%.

Continue Reading

Featured

Stock Price Newsletter – December 13, 2019

Joe Samuel

Published

on

stock market news

StockPrice Special Report: The $40 Billion Dollar Content Gold Rush

Click For Full Report


2 Biotech Stocks To Watch Before Next Week

See For Yourself


Streaming Wars and the Future of Companies Involved

Has The Time Come?

Continue Reading

Biotechnology

2 Biotech Stocks To Watch Before Next Week

A. Lawrence

Published

on

stock_price_medicine

Biotech has been one of the hottest sectors to invest in for quite a few years. Nowadays, investors are almost always on the lookout for the next big thing from among those stocks. However, when it comes to identifying stocks, an investor needs to do his fair share of research and then decide on his next course of action.

Additionally, one could also watch the market closely and keep track of the latest movements in penny stocks in order to identify potential winners. Here is a look at two biotech stocks which could be of interest to investors.

Biotech Stocks To Watch: Marinus Pharmaceuticals

The first biotech stock to bring under consideration is Marinus Pharmaceuticals Inc (NASDAQ:MRNS)  which has made significant gains on Wednesday on the back of an important announcement.

top biotech stocks to buy

On Wednesday, the company announced that it is going to make a simultaneous public offering of its common stock and private placement. The total value of these two offerings is going to be $65 million. The news resulted in a 38% bump in the stock price in yesterday’s trading session.

Earlier this week, the company announced that it has started its Phase 2 trial for its product ganaxolone as well. The medicine in question is supposed to treat tuberous sclerosis complex and it goes without saying that it is a significant milestone for Marinus.

Biotech Stocks To Watch: Diffusion Pharmaceuticals

top biotech stocks to buy now

The other biotech stock that could be worth tracking is that of Diffusion Pharmaceuticals Inc (NASDAQ:DFFN). The company announced positive data with regards to the Phase 3 study its product Trans Sodium Crocetinate (TSC) plus standard of care (SOC). The data showed that there was an improvement in the condition of patients suffering from inoperable glioblastoma multiforme.

It proved to be a major trigger for the Diffusion stock and after the announcement was made on Tuesday, the stock has rallied by as much as 31.40%. It is a stock that could be worth watching over the coming days.

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com